Bank of America Securities released a report indicating that, considering beigenes performance in the first three quarters, the projected ratio of research and development expenses for 2024 to 2026 has been increased by 1.4, 1.9, and 1.6 percentage points respectively, and the ratio of sales, general, and administrative expenses for the same period has been increased by 2, 1.6, and 1.4 percentage points. Due to the robust progress in the solid tumor pipeline, long-term revenue forecasts have also been raised.

Bank of America Securities has slightly lowered beigenes target price for its Hong Kong stock from 126.2 HKD to 125 HKD to reflect increased expenses. The rating remains at "Neutral" to reflect smooth progress in new drug development, but competition in the domestic market is fierce.